drugset / Trial / NCT00193427
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
Phase 2
Completed
75 enrolled
SCRI Development Innovations, LLC
Aventis Pharmaceuticals · collabEli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC. This study will help to better define optimal preoperative regimens for patients with resectable NSCLC. Since both of these drugs are potent radio-sensitizers, the concurrent use with radiation therapy at these weekly doses may produce not only radio-sensitization, but also considerable antitumor efficacy.
Timeline
- Start
- 2004-04
- Primary completion
- 2008-11
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 1.5 unknown | — |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |